Capabilities
From the earliest days of COVID-19, King & Spalding has been at the forefront of vaccine developments, helping our leading pharmaceutical clients develop and implement strategies to contain the legal and reputational risks throughout their journey. At this critical juncture of distribution, our COVID-19 Vaccine Rollout Task Force is drawing on our industry knowledge and client relationships to serve as a guiding light and partner to our clients.
As you will see in the resources herein, we are focused on untangling the matrix of hurdles that arise in this unchartered landscape of developing state guidance intersecting with a rapidly evolving federal landscape. We are also examining the legislation developing to advise clients on immunity provisions and helping our clients prepare for potential investigations and litigation to follow.
February 23, 2021
Mandatory Employee Vaccinations Globally: Can You Require Your Employees To Get The COVID-19 Vaccine Everywhere?
February 23, 2021
Increased Reliance on the DPA to Fight COVID-19 Has Major Impact on Supplies of Other Drugs and Therapies
February 22, 2021
FDA Issues Additional Guidance for Medical Product Developers Addressing Virus Variants
February 21, 2021
Jules Quinn comments on employer's mandatory COVID-19 vaccine policies
January 26, 2021
Healthcare partner Rick Zall joins the firm’s healthcare transactional and regulatory practice group in New York
July 24, 2020
Zack Harmon, Sumon Dantiki and Seth Lundy discuss issues at play in the development of a COVID-19 vaccine.